Portugal OTC drug maker Fancystage Unipessoal skipped identity testing of high-risk ingredients and lacked quality-unit control, FDA says.
What happened
FDA reviewed records and other information the company submitted after a March 17, 2023 request for records under section 704(a)(4) of the FD&C Act; this was a records review, not an inspection. The records showed the firm did not test each shipment of each lot of incoming components at high risk of hazardous-impurity contamination to confirm identity, and that its quality unit did not effectively approve or reject components. FDA placed the firm on Import Alert 66-40 on May 8, 2023.
What FDA found
The company did not perform at least one identity test on each incoming shipment of each lot of components, including components at high risk of carrying hazardous impurities that have caused lethal poisonings worldwide.
21 CFR 211.84(d)(1)The quality unit was not given or did not use its authority to approve or reject components, containers, closures, in-process materials, packaging, labeling, and finished drugs.
21 CFR 211.22(a)
What FDA wants
FDA tells the company to respond in writing within 30 working days describing corrections, and to send impurity test results on retained high-risk component lots or implicated finished batches within 30 calendar days, plus a risk assessment, recalls if needed, and a quality-unit remediation plan. FDA also recommends hiring a qualified CGMP consultant to do a six-system audit before resuming U.S. manufacturing.
Who should pay attention
- brands and distributors that buy OTC drugs made by this contract manufacturer
- U.S. importers and own-label sellers of children's OTC drug products
- suppliers and buyers relying on certificates of analysis for high-risk raw materials
This is a summary. Read the original letter on fda.gov.